

## Company Profile

Established in 1993, Syngene began its journey as a Contract Research Organization (CRO), providing research services to pharma and biotech companies in drug discovery. Today, the Company is an integrated Contract Research Development and Manufacturing Organization (CDMO), providing a comprehensive set of services that span the entire drug lifecycle, supporting clients from early-stage research and discovery all the way through to commercial manufacturing. With a combined focus on speed, scale, and supply chain security with diversified, qualified sourcing options, Syngene is well positioned as a strong partner for biopharmaceutical companies looking to bring new drugs to market faster and more reliably. Syngene's team of over 5,500 scientists functions as an extension to clients' research teams, pushing the boundaries of scientific discovery while solving complex problems, leveraging leading-edge technology, offering scalable solutions, and maintaining global quality standards.



## Services

Syngene serves a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. Syngene provides a comprehensive suite of services that span the entire drug development lifecycle. From early-stage research and target identification to advancing drug candidates through clinical trials and ensuring commercial-scale production of small and large molecules, Syngene's integrated approach ensures safety, efficacy, and scalability. Syngene actively incorporates cutting-edge technologies like CAR-T cells, mRNA, Antibody-Drug Conjugates (ADCs), and oligonucleotides into its service offerings. The Company has one of the world's largest Proteolysis Targeting Chimera (PROTAC) teams, with over 500 scientists working on developing targeted cancer treatments. Syngene also continuously invests in advanced technologies, including the development of a proprietary AI platform (SynAI) that enables disease and network biology understanding, leading to better target identification. Syngene's expertise spans a range of therapeutic areas, including oncology, immunology, neuroscience, metabolic disorders, and infectious diseases.

## Workforce

Around **8,000**, of which  
~ **5,500** are scientists

**26%**

Permanent  
roles filled  
by women

Around  
**10%**

Scientists  
have a  
Ph.D.

Around  
**68%**

Employees  
hold masters  
degrees

## Collaborations

Syngene collaborates with 400+ pharma and biotech companies across the globe, including 11 of the world's top 15 pharma companies. The Company's strategic partnerships and collaborations range from small biotechs to big pharma companies such as GSK, Janssen, Zoetis, and Merck KGaA, including dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb.

## Global Footprint (by number of clients)



## Patents Assigned

400+

patents assigned to clients

## Collaboration Models

Fee for Service (FFS), Full-Time Equivalent (FTE), Dedicated Centers, Outcome-based model with Service Level Agreement and Risk/Reward Milestone-based model.

## Infrastructure

2.2 Mn+ sq. ft.

qualified to meet international standards

## Listing Details

Syngene (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) listed on the **Bombay Stock Exchange (BSE)** and **National Stock Exchange (NSE)** with an Initial Public Offer (IPO) in 2015.

## Market Cap

~ 3.5 Bn USD

in FY 24

## Credit Ratings

Long-term debt rating

AA+/Stable  
(CRISIL<sup>1</sup>)

AA+/Stable  
(ICRA<sup>2</sup>)

Short-term debt rating

A1+  
(CRISIL and ICRA)

## Revenue and PAT

418 Mn USD

in FY 24

62 Mn USD

Profit After Tax (PAT)

<sup>1</sup>Credit Rating Information Services of India Limited

<sup>2</sup>Investment Information and Credit Rating Agency

## Ownership

The promoter group (primarily Biocon Limited) holds

~55%

Foreign Institutional Investors

~21%

Mutual Funds, Banks, Financial Institutions and Alternative Investment Funds

~15.8%

## ESG Highlights (FY24)

Water recycling - increased to **23%** of total consumption from **20%** in the prior year

**82%** of the total energy consumed across all campuses came from renewable sources

**~96%** of hazardous and non-hazardous waste recycled as part of the waste management strategy